PORTAGE ANNOUNCES FILING OF Q1 INTERIM FINANCIAL STATEMENTS; CORRECTION TO SALVARX LOAN NOTE SETTLEMENT ANNOUNCEMENT read more
PORTAGE ANNOUNCES RELIANCE ON TEMPORARY REGULATORY RELIEF FOR FILING ANNUAL FINANCIAL STATEMENTS read more
PORTAGE RAISES MORE THAN US$6.7 MILLION THROUGH NON-BROKERED PRIVATE PLACEMENT; TEMPORARY SYMBOL CHANGE ON OTC MARKETS read more
PORTAGE MAKES ADDITIONAL INVESTMENT IN STIMUNITY S.A.S, A PARIS-BASED CANCER IMMUNOTHERAPY COMPANY. read more
Portage makes an additional investment in Saugatuck therapeutics after achieving proof of concept read more
PORTAGE ANNOUNCES FILING OF 3RD QUARTER FINANCIAL STATEMENTS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION AND OTC TRADING read more
PORTAGE ANNOUNCES FURTHER SUBSCRIPTION OF US$950,000 IN CONVERTIBLE LOAN NOTES TO IOX THERAPEUTICS AND PROVIDES UPDATE ON CTO REVOCATION APPLICATION read more
Portage Biotech Inc. (CSE: PBT.U, OTC Markets: PTGEF) (“Portage” or the “Company”) is pleased to announce that it has been granted an extension by the Canadian Securities Exchange (the “CSE”) to remedy its default under CSE listing rules. read more
Portage makes additional investment in Stimunity S.A. a Paris-Based Cancer immunotherapy company read more
Portage posts meeting materials; trading on CSE expected to resume shortly; overview of combined Portage/SalvaRx portfolio read more
Portage Announces Results of Shareholders Meeting and Provides Update on Its Portfolio Companies read more
Biohaven announces closing of initial public offering and full exercise of underwriters’ option to purchase additional shares read more
FDA clears Biohaven’s Investigational New Drug Application For BHV-4157 and Portage To Hold Investor Conference Call to Provide Business Update read more
Portage’s Biohaven Orphan Drug Designation Request Granted for the Treatment of Spinocerebellar Ataxia read more
Portage’s Biohaven Announces Expedited Development Path for BHV-0223 Following Successful Pre-IND Interaction with FDA read more
Mr. James Mellon and Dr. Gregory Bailey (“Offerors”) Announce Additional Shares in Portage Biotech Inc. read more
Portage’s Biohaven Announce Phase I Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223 and also Appoints a CEO read more
Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research read more
Portage’s PPL Will Advance its Lead Candidate PPL-003 to an IND for Dry Eye Disease and Uveitis read more
Portage’s Biohaven Doses First Human Subject in Phase I Trial with Lead Drug Candidate BHV-0223 read more
Portage’s Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC read more
Portage’s Biohaven Raises US$4.1 Million in First Tranche of Private Placement. Portage Invests $2.5M read more
Portage Completes Non-Brokered Private Placement in Two Tranches for Total Proceeds of US$ 5,155,080 read more
Portage’s Biohaven to Begin Phase I Study in 3Q 2015 and Readying for Phase III Study Start by Q1 2016 read more
Portage’s Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product read more
Portage Announces Further Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology read more
Portage’s Biohaven Granted United States Patent for Glutamate Agents in the Treatment of Mental Disorders read more
Portage Announces Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology read more
Portage Signs a Collaborative Research and Development Agreement with U.S. National Institute of Health read more
Portage’s Biohaven Issued Notice of Allowance: Glutamate Agents in the Treatment of Mental Disorders read more
